drugset / Trial / NCT00963534
Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.
Phase 1/2
Completed
51 enrolled
Lund University Hospital
Celgene Corporation · collabMundipharma Pte Ltd. · collabRoche Pharma AG · collab
NaSingle-groupOpen-labelTreatment
Summary
In phase I: Establishing maximally tolerated dose of lenalidomide in combination with bendamustine and rituximab. In phase II: Evaluation of progression free survival with treatment with lenalidomide, bendamustine and rituximab
Timeline
- Start
- 2009-09
- Primary completion
- 2017-08
- Completion
- 2017-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bendamustine | Small molecule | 90 mg/m2 | Intravenous |
| Subject | Lenalidomide | Other / unclassified | 5 mg | — |
| Subject | Lenalidomide | Other / unclassified | 10 mg | — |
| Subject | Lenalidomide | Other / unclassified | 25 mg | — |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |